AC Immune clears first hurdle for α-synuclein PET tracer

With early proof of concept that its α-synuclein PET tracer can selectively detect toxic plaques in multisystem atrophy patients, AC Immune brings the field a step closer to non-invasively diagnosing diseases involving α-synuclein, and developing disease-modifying therapies.

At the AD/PD 2022 International Conference on Friday, AC Immune S.A. (NASDAQ:ACIU) reported that AC-12589, a PET tracer the company designed to selectively bind the toxic α-synuclein that aggregates in the brains of patients with certain neurodegenerative diseases, could be used to identify patients with the rare neurodegenerative disease multisystem atrophy (MSA). ...